Saama Technologies, Inc., a Campbell, Calif.-based AI-driven Intelligent Clinical Cloud company, received an up to $430m investment.
Backers included Carlyle (NASDAQ: CG), which will acquire a majority stake in the company, and a broad co-investor group with several healthcare-focused venture funds, including Amgen Ventures, Intermountain Ventures, Merck Global Health Innovation Fund, McKesson Ventures, Northpond Ventures, Pfizer Ventures, and Population Health Partners.
The company intends to use the funds to accelerate its strategic initiatives, including expanding its go-to-market capabilities and further investing in AI research and development.
Led by Suresh Katta, Founder and CEO, Saama provides the Life Science Analytics Cloud (LSAC), which is used by over 50 pharma and biotech companies on more than 1,500 studies. LSAC provides a unified approach to clinical trial data management and analytics. Its pre-trained AI embedded smart applications have the ability to learn the complex patterns among clinical data and provide predictive insights to accelerate the clinical research process across a variety of domains and therapeutic areas.
FinSMEs
20/10/2021